Impact of PAP therapy on hospitalization rates in Medicare beneficiaries with COPD and coexisting OSA.


Journal

Sleep & breathing = Schlaf & Atmung
ISSN: 1522-1709
Titre abrégé: Sleep Breath
Pays: Germany
ID NLM: 9804161

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 06 01 2018
accepted: 05 06 2018
revised: 29 05 2018
pubmed: 23 6 2018
medline: 18 12 2019
entrez: 23 6 2018
Statut: ppublish

Résumé

Growing evidence supports that patients with chronic obstructive pulmonary disease (COPD) and coexisting obstructive sleep apnea (OSA) have poor prognosis. This association is described as overlap syndrome. Positive airway pressure (PAP) therapy is now the preferred treatment for OSA. We hypothesized that use of PAP therapy in elderly patients with overlap syndrome would be associated with lower healthcare utilization. In this retrospective cohort study, we analyzed data from 5% national sample of fee-for-service Medicare beneficiaries with a diagnosis of COPD who were newly started on PAP therapy in 2011. We examined the effect of PAP therapy on emergency room (ER) visits and hospitalizations for all-cause and COPD-related conditions in the 1 year pre- and 1 year post-initiation of PAP therapy. In year 2011, we identified 319 patients with overlap syndrome who were new users of PAP therapy. In this cohort of patients, hospitalization rates for COPD-related conditions were significantly lower in the 1 year post-initiation of PAP therapy compared to the 1-year pre-initiation period (19.4 vs 25.4%, P value = 0.03). However, ER visits (for any cause or COPD-related conditions) and hospitalization rates for any cause did not differ significantly in the pre- and post-initiation periods. PAP therapy was more beneficial in older adults, those with higher COPD complexity, and those with three or more comorbidities. Initiation of PAP therapy in elderly patients with overlap syndrome is associated with a reduction in hospitalization for COPD-related conditions, but not for all-cause hospitalizations and ER visits.

Identifiants

pubmed: 29931497
doi: 10.1007/s11325-018-1680-0
pii: 10.1007/s11325-018-1680-0
pmc: PMC6309578
mid: NIHMS977231
doi:

Substances chimiques

VEGFA protein, human 0
Vascular Endothelial Growth Factor A 0

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

193-200

Subventions

Organisme : AHRQ HHS
ID : R01 HS020642
Pays : United States
Organisme : AHRQ HHS
ID : R24 HS022134
Pays : United States
Organisme : Agency of Healthcare Research and Quality
ID : R01-HS020642
Organisme : Patient-Centered Outcomes Research Institute
ID : R24HS022134

Références

Chest. 2005 Oct;128(4):1995-2004
pubmed: 16236847
Int J Chron Obstruct Pulmon Dis. 2018 Feb 27;13:665-674
pubmed: 29520134
Am J Respir Crit Care Med. 2003 Jan 1;167(1):7-14
pubmed: 12502472
BMC Health Serv Res. 2011 Feb 23;11:43
pubmed: 21345188
Respir Med. 2011 Apr;105(4):630-6
pubmed: 21232930
Thorax. 2009 Jul;64(7):631-6
pubmed: 19561283
JAMA. 2013 Jan 23;309(4):342-3
pubmed: 23340629
Am J Respir Crit Care Med. 1995 Jan;151(1):82-6
pubmed: 7812577
Ann Am Thorac Soc. 2015 Aug;12(8):1219-25
pubmed: 25871443
Am J Respir Crit Care Med. 2011 Feb 15;183(4):539-46
pubmed: 20656940
Hosp Pract (1995). 2016;44(1):41-7
pubmed: 26691510
Am J Respir Crit Care Med. 2010 Aug 1;182(3):325-31
pubmed: 20378728
Chest. 2012 Jan;141(1):87-93
pubmed: 21757568
Lung. 2014 Apr;192(2):251-8
pubmed: 24452812
Chest. 1996 Feb;109(2):387-94
pubmed: 8620710
Eur Respir J. 2010 Jan;35(1):132-7
pubmed: 19574323
Am J Respir Crit Care Med. 2009 Oct 15;180(8):692-700
pubmed: 19628778
Am J Epidemiol. 2013 May 1;177(9):1006-14
pubmed: 23589584
Sleep Med. 2015 Sep;16(9):1123-30
pubmed: 26298789
Lancet. 2011 Sep 10;378(9795):991-6
pubmed: 21907862
Sleep Med Rev. 2017 Apr;32:58-68
pubmed: 28169105
Clin Chest Med. 1985 Dec;6(4):651-61
pubmed: 2935359
J Clin Sleep Med. 2013 Aug 15;9(8):767-72
pubmed: 23946706
J Clin Sleep Med. 2009 Jun 15;5(3):263-76
pubmed: 19960649
Respirology. 2017 Aug;22(6):1073-1083
pubmed: 28677827
Med Care. 1998 Jan;36(1):8-27
pubmed: 9431328
Respir Med. 2013 Feb;107(2):310-6
pubmed: 23141861
Am J Respir Crit Care Med. 2012 Jan 15;185(2):152-9
pubmed: 22016446

Auteurs

Gurinder Singh (G)

Internal Medicine Residency Program, San Joaquin General Hospital, 500 W Hospital Road, French Camp, CA, 95231, USA. gspannu@sbcglobal.net.

Amitesh Agarwal (A)

Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of Texas Medical Branch (UTMB), Galveston, TX, USA.

Wei Zhang (W)

Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of Texas Medical Branch (UTMB), Galveston, TX, USA.
Office of Biostatistics, University of Texas Medical Branch (UTMB), Galveston, TX, USA.

Yong-Fang Kuo (YF)

Office of Biostatistics, University of Texas Medical Branch (UTMB), Galveston, TX, USA.
Sealy Center of Aging, University of Texas Medical Branch (UTMB), Galveston, TX, USA.

Rizwana Sultana (R)

Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of Texas Medical Branch (UTMB), Galveston, TX, USA.

Gulshan Sharma (G)

Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of Texas Medical Branch (UTMB), Galveston, TX, USA.
Sealy Center of Aging, University of Texas Medical Branch (UTMB), Galveston, TX, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH